Refine by
Cancer Cell Suppliers & Manufacturers
212 companies found
based inAu, Zurich, SWITZERLAND
Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ ...
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
based inTehran, IRAN
Pars Isotope Co is a prominent supplier and producer of radioisotopes in Iran, catering widely to the medical and industrial sectors. As the sole provider in the region, the company focuses on radiopharmaceuticals used for both the diagnosis and ...
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively ...
based inMunich, GERMANY
Therawis Pharma GmbH is a privately held, profitable oncology-specialized company with offices located in Munich, Germany, and was founded in April 2014. We provide european-wide support in medical & clinical trial development for therapeutics and ...
Exosomes (30-150 nm) are the smallest type of extracellular microvesicles (EMV), produced through inward budding multivesicular bodies (MVB), resulting in intra-luminal vesicles (ILV). ILVs are released into the extracellular media by exocytosis. ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inRaleigh, NORTH CAROLINA (USA)
Kaio's strategy is to develop and in-license technologies and therapies that enable the body’s own immune system to work more efficiently. The goal is to improve clinical outcomes for patients, increase the number and efficacy of therapeutic options ...
Kaio Therapy's Immune Activation Heat Therapy is a novel hyperthermia system that delivers precisely controlled heat at the cellular level within a tumor. Because Kaio’s IAHT elegantly induces necrosis while activating a systemic, tumor ...
based inSanta Clara, CALIFORNIA (USA)
For more than 40 years, Agilent Technologies has been the leading provider of solutions for the detection, identification, and characterization of chemical and biological compounds. From environmental testing to semiconductor manufacturing, ...
The Cas9 endonuclease kit is part of an integrated solution for in-vitro CRISPR/Cas resesarch. Use this kit for in-vitro cloning of large genes or DNA fragments without the limitations imposed by common restriction enzymes or PCR fidelity. Allows ...
based inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma. ...
based inWest Chester, PENNSYLVANIA (USA)
MTTI is a Clinical Stage Company; Transforming the lives of patients burdened with severe and life-threatening diseases. Advancing selective radiotherapeutics, EBTATE targeting neuroendocrine tumors, EBRGD for non-small cell lung cancer and ...
based inLeipzig, GERMANY
Welcome to pluriSelect, your worldwide supplier of products optimized for cell and protein separation for the research in the fields of immunology, basic science and diagnostics. Our main aim is to supply you with high quality products and best ...
based inChuo-ku, JAPAN
Sysmex has a global network of operations throughout the world. This section introduces our company profile and provides the locations of our offices and subsidiaries. Sysmex supports human health. We are an integrated company, developing and ...
Also, it takes more than one hour for the gene amplification reaction. Sysmex has developed the one-step measurement technology for cancer cell derived biomarkers (CK19mRNA) in the lymph node by optimizing ...
based inSan Francisco, CALIFORNIA (USA)
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and ...
based inSan Francisco, CALIFORNIA (USA)
Aelan uses science to propel stem cell technologies forward and deliver new medicines and diagnostics to patients. We are focused on building a strong intellectual property estate to meet the potential of future applications. Our fully integrated ...
Cancer survival rates decrease with age, in part because the efficacy of cancer therapies decline for older ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
ISET, Isolation by SizE of Tumor Cells, is based on the antibody-independent whole blood filtration approach for CTCs and micro-emboli isolation. The solution relies on the larger size of all types of CTCs as compared to the majority ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates ...
based inWaltham, MASSACHUSETTS (USA)
Evident, we’re building on this legacy with a continued commitment to pushing the limits of discovery. Today, as Evident, we’re building on a century of optical superiority to create next-generation micro-imaging solutions—combining renowned optics ...
based inSan Diego, CALIFORNIA (USA)
Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. We are pioneers in using the latest ...
Utilizing highly efficient mRNA-based gene editing, Brooklyn will precisely engineer changes in the genome of iPSC, followed by a thorough characterization of the new cell line. The gene-edited iPSC will then be used to ...